Merck & Co Inc

Most Recent

  • A person walking past the Merck logo on a wall
    Healthcare

    Why 2021 Could Be a Very Healthy Year for Merck Stock

    By Ambrish Shah
  • uploads///syringe __
    Company & Industry Overviews

    Analyst Ratings for AMAG Pharmaceuticals and Peers in February

    Of the 12 analysts covering AMAG Pharmaceuticals, three have given the stock a “buy” or higher rating, and nine have given it a “hold.”

    By Kenneth Smith
  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Major Developments for Eli Lilly and Co. in 4Q15

    Eli Lilly and Co.’s (LLY) 4Q15 segment-wise performance was positive for both its Human Pharmaceuticals and Animal Health segments.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///pill _
    Company & Industry Overviews

    GlaxoSmithKline’s Valuation on June 29

    In the first quarter, GlaxoSmithKline reported EPS of 24.60 pence on revenue of 7.2 billion pounds, a 2% fall year-over-year.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s Quarterly Revenue Trend in Q2 2018

    Pfizer (PFE) reports its revenue into two business segments: Innovative Health and Essential Health.

    By Mike Benson
  • uploads///thermometer _
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive on Merck in September

    Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Modest Revenue Growth in Fiscal 2016

    Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    Akorn’s Revenue

    In 2014, prescription pharmaceuticals generated revenue of $542.84 million, and consumer health generated revenue of $50.23 million— 91.5% and 8.5% of total revenue, respectively.

    By Peter Neil
  • uploads///Novo RV multiples
    Earnings Report

    Is Novo Nordisk Trading at a Discount or Premium?

    For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

    By Jillian Dabney
  • uploads///Chart  Animal
    Company & Industry Overviews

    This Is Eli Lilly’s Animal Health Segment

    Eli Lilly’s (LLY) Animal Health segment company, Elanco, reported a 9% YoY fall in revenues at $706 million in 3Q16, as compared to $779 million in 3Q15.

    By Mike Benson
  • uploads///Chart  Revenues
    Earnings Report

    Johnson & Johnson’s 3Q17 Revenue Estimates Could Reveal Growth

    Johnson & Johnson’s (JNJ) revenues are expected to report 8.3% growth to $19.3 billion during 3Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Consistent Performance Measurement May Improve Novartis’s R&D

    Novartis (NVS) has been focused on consistently measuring the performance of its research and development (or R&D) programs using metrics such as output, cost, returns, quality, and cycle time.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    United Therapeutics: Will Orenitram See Strong Patient Demand?

    United Therapeutics (UTHR) is confident that about higher patient demand for its oral drug, Orenitram.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///ANR
    Company & Industry Overviews

    Analysts’ Expectations for Sanofi

    According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///Avastin
    Company & Industry Overviews

    A Performance Update for Roche’s Avastin in H2 2018

    In June, the FDA approved Avastin in combination with chemotherapy followed by Avastin monotherapy.

    By Daniel Collins
  • uploads///Keytruda
    Company & Industry Overviews

    Merck’s Keytruda Had 80% Growth in the Third Quarter

    Merck & Co.’s (MRK) Keytruda generated revenues of $1.9 billion in the third quarter, reflecting an ~80% YoY growth.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///health
    Company & Industry Overviews

    Johnson & Johnson’s Valuation in February 2018

    Johnson & Johnson (JNJ) reported revenues of $20.2 billion in 4Q17, an 11.5% growth compared to 4Q16.

    By Mike Benson
  • uploads///thermometer _
    Company & Industry Overviews

    A Look at Allergan’s Valuation on August 16

    In this series, we’ll discuss Allergan’s valuation, segment and product performances, recent developments, and analyst recommendations.

    By Mike Benson
  • uploads///Pfizer revenues
    Company & Industry Overviews

    How Did Pfizer Perform in 3Q17?

    In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///GILD
    Company & Industry Overviews

    What Does Gilead Sciences’ Bottom-Line Trend Indicate?

    Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter.

    By Kenneth Smith
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Merck & Co. after 4Q17

    Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bristol-Myers Squibb Continues Revenue Growth in 3Q16

    Bristol-Myers Squibb (BMY) reported a growth of 21% to $4.9 billion in its 3Q16 results.

    By Mike Benson
  • uploads///Relative valuation
    Earnings Report

    Why Does Valeant’s Valuation Seem to Be at a Discount?

    Using relative valuation, Valeant’s forward EV-to-EBITDA multiple was 6.87x on January 28, 2016. EV-to-EBITDA multiples for Merck, Sanofi, and Pfizer were 8.99x, 9.22x, and 8.99x, respectively.

    By Jillian Dabney
  • uploads///Chart  PFE
    Company & Industry Overviews

    A Closer Look at Pfizer Stock in 1Q18

    Pfizer’s stock price has fallen ~3.5% in 1Q18, while its stock price has fallen ~2.9% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings

    Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.

    By Peter Neil
  • uploads///AKRX
    Company & Industry Overviews

    Analyzing the Cash Flows and Valuation Metrics of Akorn

    Akorn (AKRX) used up $31.6 million in operating activities in 1Q18. In comparison, the company generated operating cash flow of $126.6 million in 1Q17.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///Featured image
    Company & Industry Overviews

    A Look into Roche Holding’s Performance in Q1 2018

    In Q1 2018, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in Q1 2017.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Amgen or Merck: Which Is Controlling Expenses Better?

    In its fourth-quarter conference call, Amgen (AMGN) guided for its operating expenses being flat or lower YoY (year-over-year) in fiscal 2019.

    By Margaret Patrick
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    How Did Sanofi’s Merial Segment Perform in 2014?

    The contribution of Merial, the animal health arm of Sanofi (SNY), was ~6.0%, or ~2.1 billion euros, towards the company’s total revenues in 2014.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion Expected to Boost Keytruda’s 2017 Revenue

    On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

    By Margaret Patrick
  • uploads///Chart  USST
    Earnings Report

    Behind Allergan’s US Specialized Therapeutics Segment in 1Q17

    In 1Q17, Allergan’s US Specialized Therapeutics segment revenues rose 14.1% to $1.48 billion, as compared to $1.30 billion in 1Q16.

    By Mike Benson
  • uploads///revenue growth
    Earnings Report

    Analyzing Novo’s Revenue Growth in 3Q16

    During 3Q16, Novo Nordisk’s (NVO) net sales rose 2.8% to 27.5 billion Danish kroner from 26.8 billion Danish kroner in 3Q15.

    By Jillian Dabney
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Allergan’s Financial Guidance Look for 2016?

    Allergan (AGN) estimates that its revenues will be around $17 billion in 2016.

    By Mike Benson
  • uploads///Insys revenue
    Company & Industry Overviews

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales.

    By Kenneth Smith
  • uploads///sales estimates
    Earnings Report

    Why Analysts Expect Teva’s Revenues to Fall in the Second Quarter

    For the second quarter of fiscal 2018, Wall Street expects Teva Pharmaceutical Industries to register a YoY sales decline of 16.6%.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s Driving Pfizer’s Revenue?

    Pfizer has divided its product portfolio into two segments: Innovative Health and Essential Health. It reports revenue for both these segments.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Merck Is Getting Serious about Animal Health

    Merck’s (MRK) Animal Health segment operates in more than 140 countries worldwide. The global sales reported for 3Q16 totaled ~$865 million.

    By Mike Benson
  • uploads///valuation
    Company & Industry Overviews

    Listing the Reasons behind Pfizer’s Discounted Price-to-Earnings

    Considering the robust growth prospects for many of its products going forward, Pfizer should return to robust top line growth.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Pfizer’s 1Q16: A Valuation Cheat Sheet

    On March 28, 2016, Pfizer was trading at a forward price-to-earnings multiple of ~12.9x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What Does AstraZeneca’s Growth Platform Offer?

    The RI&A (respiratory, inflammation and autoimmunity) segment one of the company’s growth platforms, is a key area of development for AstraZeneca (AZN).

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///PE
    Company & Industry Overviews

    Understanding the Recent Fall in Bristol-Myers Squibb’s Valuation

    On October 4, 2016, Bristol-Myers Squibb (BMY) was trading at a forward PE (price-to-earnings) multiple of 16.8x. With products Opdivo and Yervoy, the company leads the immuno-oncology space.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Gardasil and What It Could Mean

    Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Venclexta Witnessed Healthy Demand Trends in 1Q17

    AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.

    By Margaret Patrick
  • Financials

    Why Tudor sold its position in Forest Laboratories?

    Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]

    By Samantha Nielson
  • uploads///Chart
    Earnings Report

    What Do Analysts Recommend for Pfizer?

    Pfizer reported EPS of $0.67 on revenue of $13.0 billion in 1Q16 against the estimated $0.56 on revenue of $12.1 billion in 1Q16.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analyst Recommendations for AstraZeneca in June 2017

    In 1Q17, AstraZeneca (AZN) reported revenues close to $5.4 billion, which is a fall of around 12.0% on a YoY (year-over-year) basis.

    By Margaret Patrick
  • uploads///Chart  Gardasil
    Company & Industry Overviews

    Merck’s Gardasil and Other Human Vaccines in 3Q17

    Merck & Co.’s (MRK) Gardasil franchise reported total sales of $675 million in3Q17, a 22% fall compared to $860 million in 3Q16.

    By Mike Benson
  • uploads///Actual Vs Estimate
    Earnings Report

    Why Novo Nordisk Fell after Its 4Q15 Earnings Release

    After the announcement of Novo Nordisk’s earnings for 4Q15 and fiscal 2015, the stock tumbled by ~6%.

    By Jillian Dabney
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Post-1Q18 Valuation

    In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88.

    By Mike Benson
  • uploads///Vaccine Franchise
    Company & Industry Overviews

    How Merck’s Vaccines Business Is Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.

    By Daniel Collins
  • Financials

    Why did Tudor buy Intercontinental Exchange?

    Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]

    By Samantha Nielson
  • uploads///microbiology _
    Earnings Report

    Expectations from Novartis’s 1Q18 Earnings

    Novartis is set to release its 1Q18 earnings on April 19, 2018. Analysts expect it to report earnings per share of $1.28.

    By Mike Benson
  • uploads///Select Generic Pharma Companies Sales by Geo
    Healthcare

    What Are Biosimilars and Why Do They Benefit Generic Pharma?

    BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]

    By VanEck
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///medic _
    Company & Industry Overviews

    Analyzing Merck’s Revenue in 1Q18

    Merck (MRK), one of the largest pharmaceutical companies worldwide, reported its 1Q18 results on May 1.

    By Mike Benson
  • uploads///Chart  MRK
    Company & Industry Overviews

    How Merck & Co. Stock Performed in 1Q18

    Merck & Co. stock has fallen ~6.4% in 1Q18, while it’s fallen ~5.2% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Spectrum Pharmaceuticals Pipeline
    Company & Industry Overviews

    An Overview of Spectrum Pharmaceuticals’ Drug Pipeline

    Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.

    By Kenneth Smith
  • uploads///Graph
    Earnings Report

    AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance

    Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

    By Margaret Patrick
  • uploads///PFE MDVN deal
    Company & Industry Overviews

    What’s the Story behind the Pfizer-Medivation Deal?

    Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

    By Jillian Dabney
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    The price-to-earnings (or PE) multiple represents what one share can buy an equity investor.

    By Mike Benson
  • uploads///thumbs up _
    Company & Industry Overviews

    Merck Beat Consensus Revenue and EPS Estimates in Q4

    In the fourth quarter, Merck reported total revenues of $11.0 billion—a rise of 5% YoY (year-over-year) on a reported basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Merck’s Animal Health Segment Did in 1Q18

    In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.

    By Mike Benson
  • uploads///reent wins
    Company & Industry Overviews

    Inside Bristol’s Key to Success: Multiple Labels for Opdivo

    Opdivo’s significant regulatory advances over the past quarter include approval for head and neck cancer indications, among others.

    By Jillian Dabney
  • uploads///syringe _
    Earnings Report

    Biogen: Analysts’ Views before Its Second-Quarter Results

    On July 24, Biogen (BIIB) is scheduled to release its second-quarter earnings results. Analysts expect Biogen to report sales of $3.3 billion.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Innovative Research in Vaccines May Boost Pfizer’s Revenues

    Wall Street analysts have projected that Prevnar revenues will fall year-over-year by about 2.8%, from $6.2 billion in 2015 to $6.0 billion in 2016.

    By Margaret Patrick
  • uploads///expenses
    Company & Industry Overviews

    Gilead Sciences Focuses on a Strong Inorganic Growth Strategy

    Gilead Sciences witnessed falling revenues in the past few quarters. Its growth is expected to be revived through new products and mergers and acquisitions.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///ZTS
    Financials

    Pershing Square takes 8.5% stake in Zoetis

    Pershing Square Capital Holdings added a new position in Zoetis Inc. (ZTS), which accounts for 1.52% of Pershing Square’s portfolio for the third quarter that ended in September 2014.

    By Samantha Nielson
  • uploads///STOCK
    Earnings Report

    MYL Stock Down ~3% since Its Q2 2018 Results on August 8

    The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion.

    By Sarah Collins
  • uploads///pill _
    Earnings Report

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.

    By Mike Benson
  • uploads///joshua coleman  unsplash
    Company & Industry Overviews

    Pfizer Expands Its Investment Portfolio through Pfizer Ventures

    On June 6, Pfizer announced that it would invest ~$600 million in biotechnology and emerging growth companies through Pfizer Ventures.

    By Mike Benson
  • uploads///segment wise performance
    Earnings Report

    Will Pharmaceuticals Keep Fueling J&J’s Performance in Q2 2018?

    The majority of Johnson & Johnson’s sales come from its pharmaceuticals division. The company also operates across medical devices and consumer business segments.

    By Sarah Collins
  • uploads///headache _
    Earnings Report

    What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings

    GlaxoSmithKline is set to release its 1Q18 earnings on April 25, 2018.

    By Mike Benson
  • uploads///GILD oversold
    Company & Industry Overviews

    Is Gilead Sciences Stock Oversold?

    When compared with its estimated $30.2 billion total revenue for 2016, Gilead Sciences’s (GILD) $99 billion market capitalization on November 23 seemed to be at a greater discount. GILD had a forward PE ratio of ~7.0x against its peers’ average PE of ~12.1x.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Novartis’s 1Q16 Earnings Got a Neutral Response from Investors

    Novartis (NVS) released its 1Q16 earnings on April 21, 2016. It reported top-line growth of 1% at constant exchange rates for 1Q16—compared to 1Q15.

    By Mike Benson
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.